# Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection

> **NCT01653236** · PHASE3 · UNKNOWN · sponsor: **Theodor Bilharz Research Institute** · enrollment: 40 (estimated)

## Conditions studied

- Genotype 4 Chronic Hepatitis C Infection

## Interventions

- **DRUG:** Boceprevir
- **DRUG:** Peginterferon alfa-2b
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT01653236
- **Lead sponsor:** Theodor Bilharz Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-12
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2014-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01653236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01653236, "Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01653236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*